These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2011-002207-15 A prospective study with beta-blockers and ACE-inhibitors in patients operable breast cancer experiencing mild cardiac toxicity during treatment with anthracycline and/or trastuzumab Studio prospe... not-yet-due
Ongoing 2012-002128-33 Open-Label, Phase II Study of Trastuzumab in Combination with Lapatinib or Pertuzumab in Combination with Trastuzumab in Patients with HER2-positive Metastatic Colorectal Cancer: the HERACLES Trial (H... not-yet-due
Exempt 2014-002460-33 ANTI MEK THERAPY WITH REFAMETINIB TO PREVENT RESISTANCE TO EGFR-TARGETED TREATMENT IN METASTATIC COLORECTAL CANCERS not-yet-due
Ongoing 2014-005018-47 A PHASE II, RANDOMIZED, MULTICENTER STUDY TO ASSESS THE EFFICACY OF NAB-PACLITAXEL-BASED DOUBLET AS FIRST LINE THERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY (CUP): the AGNOSTOS trial A phase I... not-yet-due
Ongoing 2015-000866-72 Feasibility, efficacy and safety of Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin and Doxorubicin in patients with peritoneal carcinomatosis from colorectal, ov... not-yet-due
Ongoing 2016-002597-12 A PHASE II TRIAL OF RECHALLENGE WITH PANITUMUMAB DRIVEN BY RAS CLONAL-MEDIATED DYNAMIC OF RESISTANCE. THE CHRONOS TRIAL. STUDIO DI FASE II CON PANITUMUMAB “RE-CHALLENGE” GUIDATA DALLA DINAMICA DEL... not-yet-due
Ongoing 2018-000230-35 Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian/tubes and primary of peritoneum cancer. - TROOPS trial (TRabectedin plus Olaparib in advanced Ova... not-yet-due
Ongoing 2020-004057-71 miRNA100 as predictor of response to anti-endocrine treatment in luminal-HER2 negative breast cancer. a prospective validation clinical trial STUDIO PROSPETTICO DI VALIDAZIONE DEL RUOLO DELL’ESPRES... not-yet-due